- Home
- GSHD vs RAPP Comparison
GSHD vs RAPP Comparison
Compare GSHD & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GSHD | RAPP |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GSHD | RAPP |
|---|---|---|
| Price | $59.91 | $44.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $72.50 | $48.50 |
| AVG Volume (30 Days) | ★ 266.0K | 253.6K |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $18.53 | N/A |
| P/E Ratio | $54.98 | ★ N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $33.68 | $23.75 |
| 52 Week High | $84.36 | $52.93 |
Technical Indicators
Market Signals| Indicator | GSHD | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 39.46 | 41.33 |
| Support Level | $40.71 | $38.95 |
| Resistance Level | $76.20 | $49.78 |
| Average True Range (ATR) | 2.96 | 1.95 |
| MACD | -1.89 | -0.91 |
| Stochastic Oscillator | 23.59 | 13.42 |
Price Performance
Historical ComparisonAbout GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
About RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.